Human tumor antigens are ready to fly

Advances in Immunology

Volumn 62, Issue , 1996, Pages 217-256

  Henderson, Robert A ^a   Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; GENE INSERTION; GENE MUTATION; HLA SYSTEM; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; SEQUENCE ANALYSIS; T LYMPHOCYTE; TUMOR REJECTION; WART VIRUS;

EID: 0029892793     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (174)

1. Acres, R. B., Hareuveni, ML, Balloul, J.-M., and Kieny, M.-P. (1993). Vaccinia virus MUC1 immunization of mice: Immune response and protection against growth of murine tumors bearing the MUC1 antigen. J. Immunother. 14, 136-143.
2. Adema, G. J., de Boer, A. J., Van't Hullenaaar, R., Denijn, M., Ruiter, D. J., Vogel, A. M., and Figdor, C. G. (1993). Melanocyte leneage-speciflc antigens recognized by monoclonal antibodies NKI-beteb, HMB-50 and HMB-45 are encoded by a single cDNA. Am. J. Pathol. 143, 1579-1586.
3. Angelopoulou, K., Diamandis, E., Sutherland, D., Kellen, J. A., and Bunting P. S. (1994). Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer 58, 480-487.
4. Anichini, A., Maecalli, C., Mortarini, R,, Salvi, S., Arabella, M., Suarcina, P., Herlyn, M., and Parmiani, G. (1993). Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J. Exp. Med. 177, 989-998.
5. Apostolopoulos, V., Xing, P.-X., and McKenzie, I. F. C. (1994). Murine immune response to cells transfected with human MUC1: Immunization with cellular and synthetoc antigens. Cancer Res. 54, 5186-5193.
6. Bakker, A. B. H., Schreurs, M. W. J., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., and Figdor, C. (1994). Melanocyte lineage-specific antigen gplOO is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179, 1005-1009.
7. Bakker, A. B. H., Schreurs, W. J., Tafazzul, G., de Boer, A. J., Kawakami, Y., Adema, G. J., and Figdor, K. (1995). Identification of a novel peptide derived from the melanocytespecific GP100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int. J. Cancer 62, 97-102.
8. Barnd, D. L., Lan, M., Metzgar, R. S., and Finn, O. J. (1989). Specific, MHC-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA 86, 7159-7163.
9. Baskar, S., Azarenko, V., Garcia Marschall, E., Highes, E., and Ostrand-Rosenberg, S. (1994). MHC class II-transduced tumor cells induce long-term tumor-specific immunity in autologous mice. Cell. Immunol. 155, 123-133.
10. Ben-Mahrez, K., Thierry, D., Sorokine, I., Danna-Muller, A., and Kohiyama, M. (1988). Detection of circulating antibodies against c-myc protein in cancer patient sera. Br. J. Cancer 57, 529-534.
11. Boel, P., Wildmann, C., Sensi, M., Brasseur, R., Renauld, J.-C, Coulie, P., Boon, T., and van der Bruggen, P. (1995). BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic lymphocytes. Immunity 2, 167-175.
12. Brasseur, F., Rimoldi, D., Lienard, D., Lethe, B., Carrel, S., Arienti, F., Suter, L., Vanwijck, R., Bourlond, A., Humblet, Y., Vacca, A., Conese, M., Lahaye, T., Degiovanni, G., Deraemaecker, R., Beauduin, M., Sastre, X., Salmon, E., Dreno, B., Jager, E., Knuth, A., Chevreau, C., Suciu, S., Lachapelle, M., Pouillart, P., Parmiani, G., Lejeune, F., Cerottini, J.-C., Boone, T., and Marchand, M. (1996). Expression of MAGE genes in primary and metastatic cutaneous melanomas. Int. J. Cancer., in press.
13. Brichard, V., Van Pel, A., Wolfel, T., Wolfel, C., De Plaen, E., Lethe, B., Coulie, P., and Boon, T. (1993). The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 m elanoma. J. Exp. Med. 178, 489-495.
14. Burchell, J., Durbin, H., and Taylor-Papdimitriou, J. (1983). Complexity of expression of antigenic determinants recognized by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant mammary epithelial cells. J. Immunol. 131, 508-511.
15. Carubia, J. M., Yu, R. K., Macaela, L. J., Kirkwood, J. M., and Varga, J. M. (1984). Gangliosides of normal and neoplastic human melanocytes. Biochem. Biophys. Res. Com-mun. 120, 500-504.
16. + cytotoxic T lymphocytes. J. Exp. Med. 181, 363-368.
17. Cavallo, F., Giovarelli, M., Gulino, A., Vacca, A., Scala, G., and Forni, G. (1994). Interleukin-induced tumor immunogenicity. Immunol. Ser. 61, 183-193.
18. Celis, E., Fikes, J., Wentworth, P., Sidney, J., Southwood, S., Maewal, A., Del Guercio, M. F., Sette, A., and Livingston, B. (1994a). Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol. Immunol. 31, 1423-1430.
19. Celis, E., Tsai, V., Crimi, C., DeMars, R., Wentworth, P. A., Chesnut, R. W., Grey, H. M., Sette, A., and Serra, H. M. (1994b). Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA 91, 2105-2109.
20. Cheever, M. A., Disis, M. L., Bernhard, H., Gralow, J. R., Hand, S. L., Huseby, E. S., Quin, H. L., Takahashi, M., and Chen, W. (1995). Immunity to oncogenic proteins. Immunol. Rev. 145, 33-60.
21. Conry, R. M., LoBuglio, A. F., Kantor, J., Schlom, J., Loechel, F., Moore, S. E., Sumerel, L. A., Barlow, D. L., Abrams, S., and Curiel, D. T. (1994). Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res. 54, 1164-1168.
22. Conry, R. M., LoBuglio, A. F., Loechel, F., Moore, S. E., Sumerel, L. A., Barlow, D. L., and Curiel, D. T. (1995). A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther. 2, 59-65.
23. y determinants in urothelial carcinoma. Cancer Res. 48, 4113-4120.
24. Coulie, P. G., Brichard, V., Van Pel, A., Wolfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Larquin, C., Szikora, J.-P., Renauld, J.-C, and Boone, T. (1994). A new gene coding for a differentiation antigen recognized by autologous cytolytic lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180, 35-42.
25. Coulie, P. G., Lehman, F., Lethe, B., Herman, J., Lurquin, C., Andrawiss, M., and Boon, T. (1995). A mutated intron sequence codes for an epitope for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA 92: 7976-7980.
26. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engehard, V. H., Hunt, D. F., and Slingluff, C. L., Jr. (1994). Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264, 716-719
27. Crawford, L. V., Pirn, D. C, and Bulbrook, R. D. (1982). Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer. 30,403-408.
28. + T cells that provide contact-dependent bystander help to B cells. J. Immunol. 149, 3157-3165.
29. Davidoff, A. M., Iglehart, J. D., and Marks, J. R. (1992). Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancer. Proc. Natl. Acad. Sci. USA 89, 3439-3442.
30. De Plaen, E., Arden, K., Traversari, C., Gaforio, J. J., Szikora, J.-P., De Smet, C., Brasseur, F., van der Bruggen, P., Lethe, B., Lurquin, C., Brasseur, R., Chomez, P., De Backer, O., Cavanee, W., and Boon, T. (1994). Structure, chromosomal localization and expression of twelve genes of the MAGE family. Immunogenetics 40, 360-371.
31. Ding, L., Lalani, E., Reddish, M., Koganty, R., Wong, T., Samuel, J., Yacyshyn, M. B., Meikle, A., Fung, P. Y. S., Taylor-Papadimitriou, J., and Longenecker, B. M. (1993). Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: Effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother. 36, 9-17.
32. Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, A. E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., Livingston, R. B., Moe, R., and Cheever, M. (1994). Existent T-cell and antibody immunity to Her-2/neu protein in patients with breast cancer. Cancer Res. 54, 16-20.
33. Domenech, N., Henderson, R. A., and Finn, O. J. (1995). Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J. Immunol. 155, 47
34. Drebin, J. A., Link, V. C., and Greene, M. I. (1988). Monoclonal antibodies specific for the neu oncogene-encoded pl85 molecule exert synergistic anti-tumor effects in vivo. Oncogene 2, 273-277.
35. Eades-Perner, A. M., and Zimmerman, W. (1995). Carcinoembryonic antigen-transgenic mice: A model for tumor immunotherapy. Tumor Biol. 16, 56-61.
36. Engelhard, V. H. (1994). Structure of peptides associated with class I and class II MHC molecules. Annu. Rev. Immunol. 12, 181-207.
37. Fagerberg, J., Hjelm, A.-L., Ragnhammar, P., Frodin, J.-E., Wigzel, H., and Mellstedt, H. (1995). Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T cells. Cancer Res. 55, 1824-1827.
38. Finlay, C. A., Hinds, P. W., and Levine, A. J. (1989). The p53 proto-oncogene can act as a suppressor of transformation. Cell 57, 1083-1093.
39. Finn, O. J., Jerome, K., Henderson, R. A., Pecher, G., Domenech, N., Magarian-Blander, J., and Barratt-Boyes, S. M. (1995). MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 145, 61-89.
40. Fisk, B., Blevins, T. L., Wharton, J. T., and Ioannides, C. G. (1995). Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte l i n e s. J. Exp. Med. 181, 2109-2117.
41. Flamand, V., Sornasse, T., Thielemans, K., Demanet, C., Bakkus, M., Tielemans, F., Leo, O., Urbain, J., and Moser, M. (1994). Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24, 605-610.
42. Fleischhauer, K., Avila, D., Vilbois, F., Traversari, C., Bordignon, C., and Wallny, H.-J. (1994). Characterization of natural peptide ligands for HLA-B°4402 and B°4403: Implications for peptide involvement in allorecognition of a single amino acid change in the HLA-B44 heavy chain. Tissue Antigens 44, 311-317.
43. + T cells recognize a peptide corresponding to a common mutation (13Gly → Asp). Int. J. Cancer 56, 40-45.
44. Fossum, B., Gedde-Dahl, T., Hansen, T., Eriksen, J. A., Thorsby, E., and Gaudemack, G. (1993). Overlapping epitopes encompassing a point mutation (12 Gly → Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells. Eur. J. Immunol. 23, 2687-2691.
45. Gaugler, B., Van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethe, B., Brasseur, F., and Boon, T. (1994). Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179, 921-930.
46. Gendler, S., Lancaster, C., Taylor-Papadimitriou, J., Duhig, T., Peat, N., Burchell, J., Pemberton, L., Lalani, E.-N., and Wilson, D. (1990). Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 265, 15286.
47. Girling, A., Bartkova, J., Gendler, S., Gillet, C., Taylor, and Papdimitriou, J. (1989). A core protein of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int. J. Cancer 43, 1072-1075.
48. Gold, D. V., and Mattes, M. J. (1988). Monoclonal antibody B72.3 reacts with a core structure of O-linked carbohydrates. Tumor Biol. 9, 137-144.
49. Hakamori, S. (1985). Aberrant glycosylation in cancer-cell membranes as focused on glycolipids: Overview and perspectives. Cancer Res. 45, 2405-2414.
50. Hand, P. H., Robbins, P. F., Salgaller, M. L., Poole, D. J., and Schlom, J. (1993). Evaluation of human carcinoembryonic antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies. Cancer Immunol. Immunother. 36, 65-75.
51. Hareuveni, M., Gautier, C., Kieny, M.-P., Wreschner, D., Chambon, P., and Lathe, R. (1990). Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc. Natl. Acad. Sci. USA 87, 9498-9502.
52. Haurum, J. S., Arsequell, G., Lellouch, A. C, Wong, S. Y. C, Dwek, R. A., McMichael, A. J., and Elliot, T. (1994). Recognition of carbohydrate by major histocompatibility complex class I-restricted glycopeptide-specific cytotoxic T lymphocytes. J. Exp. Med. 180, 739-744.
53. Helling, F., Zhang, S., Shang, A., Adluri, S., Calves, M., Koganty, R., Longenecker, M. B., Yao, T-Y., Oettgen, H. F., and Livingston, P. O. (1995). GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer. Res. 55, 2783-2788.
54. Hellstrom, K. E., and Hellstrom, I. (1969). Cellular immunity against tumor specific antigens. Adv. Cancer Res. 12, 167-223.
55. Hellstrom, K. E., Hellstrom, I., and Chen, L. (1995). Can co-stimulated tumor immunity be theraperically efficacious? Immunol. Rev. 145, 167-178.
56. Hentu, P., Liao, S., and Vihko, P. (1992). Androgens up-regulate the human prostate-specific antigen messanger ribonucleis acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in LNCaP cell line. Endocrinology 130, 766-772.
57. Herlyn, M. Steplewski, Z., Herlyn, D., and Kaprowski, H. (1979). Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc. Natl. Acad. Sci. USA 76, 1438-1452.
58. Hernando, J. J., von Kleist S., and Grunert, F. (1994). A repertoire of monoclonal antibodies reveals extensive epitope heterogeneity in CEA purified from neoplasms originating from different organs. Int. J. Cancer. 56, 655-661.
59. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. (1991). p53 mutations in human cancer. Science (Washington DC) 253, 49-53.
60. Houbiers, J. G. A., Nijman, H. W., Van der Burg, S. H., Drijfhout, J. W., Kenemans, P., Van de Velde, C. J. H., Brand, A., Momburg, F., Kast, W. M., and Melief, C. J. M. (1993). In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild type p53. Eur. J. Immunol. 23, 2072-2077.
61. Howley, P. M. (1991). Role of human papillomaviruses in human cancer. Cancer Res. 51, 5019-5022.
62. Jerome, K. R., Barnd, D. L., Bendt, K. M., Boyer, C. M., Taylor-Papadimitriou, J., McKenzie, I. F. C, Bast, R. C, Jr., and Finn, O. J. (1991). Cytotoxic T lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51,2908-2916.
63. + T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J. Immunol. 146, 3235-3241.
64. Kaminski, M. S., Kitamura, K., Maloney, D. G., and Levy, R. (1987). Idlotype vaccination against murine B cell lymphoma: Inhibition of tumor immunity by free idiotype protein. J. Immunol. 138, 12
65. Kang, X., Kawakami, Y., El-Gamil, M., Wang, R., Sakaguchi, K., Yannelli, J. R., Appella, E., Rosenberg, S. A., and Robbins, P. (1995). Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor infiltrating lymphocytes. J. Immunol. 155, 1343-1348.
66. Kantor, J., Irvine, K., Abrams, S., Snoy, P., Olsen, R., Greiner, J., Kaufman, H., Eggensperger, D., and Schlom, J. (1992). Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res. 52, 6917-6925.
67. Kast, W. M., Brandt, R. M. P., Sidney, J., Drijfhout, J.-W., Kubo, R. T., Grey, H. M., Melief, C. J. M., and Sette, A. (1994). Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol. 152, 3904-3912.
68. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S., Mild, T., and Rosenberg, S. (1994a). Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91, 3515-3519.
69. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. (1994b). Identification of the immunodominant epitope of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180, 347-352.
70. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Mild, T., and Rosenberg, S. A. (1994c). Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91, 6458-6462.
71. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P. F., Sette, A., Appella, E.,and Rosenberg, S. (1995). Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154, 3961-3968.
72. Kohler, G., and Milstein, C. (1976). Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol. 6, 511-519.
73. Kotera, Y., Fontenot, J. D., Pecher, G., Metzgar, R. S., and Finn, O. J. (1994). Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res. 54, 2856-2860.
74. Kumer, U. and Staerz, U. (1993). Concepts of antibody-mediated cancer therapy. Cancer Invest. 11, 174-184.
75. Kwak, L. W., Campbell, M. J., Czerwinski, D. K., Hart, S., Miller, R., and Levy, R. (1992). Induction of immune responses in patients with B-cell lymphoma against the surfaceimmunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327, 1209-1215.
76. Labrecque, S., Naftaly, N., Thomson, D., and Matlashevski, G. (1993). Analysis of the antip53 response in cancer patients. Cancer Res. 53, 3468-3471.
77. Lanzavecchia, A. (1995). How can cryptic epitopes trigger autoimmunity? J. Exp. Med. 181, 1945-1948.
78. Levesque, M., Yu, H., D'Costa, M, and Diamantis, E. P. (1995). Prostate specific antigen expression by various t u m o r s. J. Clin. Lab. Anal. 9, 123-128.
79. Levy, R., and Miller, R. (1990). Therapy of lymphoma directed at idiotypes. J. Natl. Cancer Inst. 10, 61-68.
80. Livingston, P. O. (1995). Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccine. Immunol. Rev. 145, 147-166.
81. Livingston, P. O., Natoli, E. J., Jr., Jones Calves, M., Stockert, E., Oettgen, H. F., and Old, L. J. (1987). Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients by immunization. Proc. Natl. Acad. Sci. USA 84, 2911-2915.
82. Livingston, P. O., Ritter, G., Srivastava, P., Calves, M. J., Oettgen, H. F., and Old, L. J. (1989). Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res. 49, 7045-7050.
83. Livingston, P. O., Wong, G. Y., Adluri, S., et al. (1994). A randomized trial of adjuvant vaccination with BCG versus BCG plus the melanoma ganglioside GM2 in AJCC stage III melanoma patients. J. Clin. Oncol. 12, 1036-1044.
84. Lloyd, K. O. (1987). Blood group antigens as markers for normal cell differentiation and malignant change in human tissues. Am. J. Clin. Pathol. 87, 129-139.
85. Lloyd, K. O. (1990). Molecular characteristics of tumor antigens. Immunol. Allergy Clin. North Am. 10, 765-779.
86. Lloyd, K. O. (1991). Humoral immune responses to tumor-associated carbohydrate antigens. Cancer Biol. 2, 421-431.
87. Lloyd, K. O., and Old, L. J. (1989). Human monoclonal antibodies to glycolipids and other carbohydrate antigens: Dissection of the humoral immune response in cancer patients. Cancer Res. 49, 3445-3451.
88. Lupu, R., Colomer, R., Kannan, B., and Lippman, M. (1992). Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc. Natl. Acad. Sci. USA 89, 2287-2291.
89. - transplantation antigen P91A: The mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58, 293-303.
90. Maccario, R., Revello, M. G., Comoly, P., Montagna, D., Locatelli, F., and Gerna, G. (1993). HLA-unrestricted killing of HSV-1-infected mononuclear cells. Involvement of either γ/δ or α/β human cytotoxic T lymphocytes. J. Immunol. 150, 1437-1445.
91. MacLean, G. D., Bowen-Yacyshyn, M. B., Samuel, J., Meikle, A., Stuart, G., Nation, J., Poppema, S., Jerry, M., Koganty, R., Wong, T., and Longenecker, B. M. (1992). Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friendenreich) determinant using a synthetic carbohydrate a n t i g e n. J. Immunother. 11, 292-305.
92. MacLean, G. D., Reddish, M., Koganty, R. R., Wong, T., Gandhi, S., Smolensky M., Samuel, J., Nabholtz, J. M., and Longenecker, B. M. (1993). Immunization of breast cancer patients using a synthetic sialyl-Tn glycocongugate plus Detox adjuvant. Cancer Immunol. Immunother. 36, 215-222.
93. Majuri, M. L., Hakkarainen, M., Paavonen, T., and Renkonen, R. (1994). Carcinoembryonic antigen is expressed on endothelial cells. A putative mediator of tumor cell extravasation and metastasis. APMIS 102, 432-438.
94. Mandelboim, O., Berke, G., Fridkin, M., Feldman, M., Eisenstain, M., and Eisenbach L. (1994). CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369, 67-71.
95. Marxsen, J., Schmiegel, W., Roder, C., Harder, R., Juhl, H., Henne-Bruns, D., Kremer, B., and Kalthoff, H. (1994). Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. B r. J. Cancer 70, 1031-1034.
96. Matzinger, P. (1994). Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045.
97. Mattes, M. J., Thomson, T. M., Old, L. J., and Lloyd, K. O. (1983). A pigmantationassociated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int. J. Cancer 32, 717-721.
98. Meeker, T., Lowder, J., Cleary, M. L., Stewart, S., Warnke, R., Sklar, J., and Levy, R. (1985). Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N. Engl. J. Med. 312, 1658-1665.
99. Melief, C. J. M., and Kast, W. M. (1995). T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 146, 167-177.
100. Michaelsson, E., Malmstrom, V., Reis, S., Engstrom, A., Burkhardt, H., and Holmdahl, R. (1994). T cell recognition of carbohydrates on type II collagen. J. Exp. Med. 180,745-749.
101. Mizoguchi, H., O'Shea, J. J., Longo, D. L., Loeffler, C. M., McVicar, D., and Ochoa, A. C. (1992). Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258, 1795-1797.
102. Muraro, R., Wundulich, D., Thor, A., Lundy, J., Noguchi, P., Cunningham, R., and Schlom, J. (1985). Definition by monoclonal antibodies of a repertoire of epitopes on CEA differentially expressed in human colon carcinomas versus normal tissues. Cancer Res. 45, 5769-5780.
103. Muscatelli, F., Walker, A. P., De Plaen, E., Stafford, A. N., and Monaco, A. P. (1996). Isolation and characterization of a new MAGE hene family in Xp21.3 region. Proc. Natl. Acad. Sci. USA 92, 4987-4991.
104. O'Boyle, K. P., Zamore, R., Adluri, S., Cohen, A., Kemeny, N., Welt, S., Lloyd, K. O., Oettgen, H. F., Old, L. J., and Livingston, P. O. (1992). Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. Cancer Res. 52, 5663-5667.
105. Old, L. J. (1981). Cancer immunology: The search for specificity. Cancer Res. 41,361-375.
106. Pardoll, D. M. (1993). New strategies for enhancing the immunogenicity of tumors. Curr. Opinion Immunol. 5, 719-725.
107. Peles, E., Bacus, S., Koski, R., Lu, H., Wen, D., Ogden, S., Levy, R., and Yarden, Y. (1992). Isolation of the neu/Her-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69, 205-216.
108. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C, Yoshino, I., and Eberlein, T. J. (1995). Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu derived peptide. Proc. Natl. Acad. Sci. USA 92, 432-436.
109. Press, M., Cordon-Cardo, C., and Slamon, D. (1990). Expression of HER-2/neu protooncogene in normal human adult and fetal tissues. Oncogene 5, 953-962.
110. Pukel, C. S., Lloyd, K. O., Travassos, L. R., Dippold, W. G, Oettgen, H. F., and Old, L. J. (1982). GD3, a prominent ganglioside of human melanoma. Detection and characterization by a mouse monoclonal antibody. J. Exp. Med. 155, 1133-1147.
111. Rainov, N. G., Dobberstein, K.-U., Fittkau, M., Bahn, H., Holzhausen, H.-J., Gantchev, L., and Burkert, W. (1995). Absence of p53 autoantibodies in sera from glioma patients. Clin. Cancer Res. 1, 775-781.
112. Resnick, R. M., Cornelissen, M. T. E., Wright, D. K., Eichinger, G. H., Fox, H. S., ter Schegget, J., and Manos, M. M. (1990). Detection and typing of human papillomavirus in archival cervical specimens by DNA amplification with consensus primers. J. Natl. Cancer Inst. 82, 1477-1484.
113. Ressing, M. E., Sette, A., Brandt, R. M. P., Ruppert, J., Wentworth, P. A., Hartman, M., Oseroff, C., Grey, H. M, Melief, C. J. M., and Kast, W. M. (1995). Human CTL epitopes encoded by human papillomavirus type E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A0201-binding peptides. J. Immunol. 154, 5934-5943.
114. Riethmuller, G., Schneider-Gadicke, E., Schlimok, G., Schmiegel, W., Raab, R., Hofken, K., Gruber, R., Pichelmaier, H., Hirche, H., Pichlmyr, R., Buggisch, P., Witte, J., and the German Cancer Aid 17-1A Study Group (1994). Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343, 1177-1183.
115. Roth, J. A. (Ed.) (1986). "Monoclonal Antibodies in Cancer. Advances in Diagnosis and Treatment." Futura, Mount Kisco, NY.
116. Rughetti, A., Turchi, V., Ghetti, C. A., Scambia, G., Panici, P. B., Ronucci, G., Mancuso, S., Frati, L., and Nutti, M. (1993). Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res. 53, 2457-2459.
117. Salemi, S., Caporossi, A. P., Boffia, L., Longobardi, M. G., and Barnaba, V. (1995). HIVgpl20 activates autorective CD4-specific T cell responses by unveiling of hidden CD4 peptides during processing. J. Exp. Med. 181, 2253-2257.
118. Sato, T., Maguire, H. C, Mastrangelo, M. J., and Berd, D. (1995). Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine. Clin. Immunol. Immunopath. 74, 35-43.
119. Schiirmacher, V. (1992). Immunity and metastases: In situ activation of protective T cells by virus modified cancer vaccines. Cancer Survey 13, 129-154.
120. Schlichtholtz, B., Legros, Y., Gillet, D., Gailard, C., Marty, M., Lane, D., Calvo, F., and Soussi, T. (1992). The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 52, 6380-6384.
121. Schreiber, H., Ward, P. L., Rowley, D. A., and Stauss, H. J. (1988). Unique tumor-specific antigens. Annu. Rev. Immunol. 6, 465-483.
122. Schuessler, M. A., Pintado, S., Welt, S., Real, F. X., Xu, M., Melamed, M. R., Lloyd, K. O., and Oettgen, H. F. (1991). Blood-group and blood-group-related antigens in normal pancreas and pancreas cancer: Enhanced expression of precursor type 1, Tn and Sialyl-Tn in pancreas cancer. Int. J. Cancer. 47, 180-187.
123. Seed, B., and Aruffo, A. (1987). Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc. Natl. Acad. Sci. USA 84, 3365-3369.
124. Seedorf, K., Oltersdorf, T., Krammer, G., and Rowekamp, W. (1987). Identification of early proteins of the human papillomavirus type 16 (HPV16) and type 18 (HPV18) in cervical carcinoma cells. EMBO J. 6, 139-144.
125. Sercarz, E. E., Lehmann, P. V., Ametani, A., Benichou, G., Miller, A., and Moudgil, K. (1993). Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11, 729-766.
126. Shievely, J., and Beatty, J. (1985). CEA related antigens: Molecular, biological and clinical significance. CRC Crit. Rev. Oncol. Hematol. 2, 355-399.
127. Sibille, C., Chomez, P., Wildmann, C., Van Pel, A., De Plaen, E., Maryanski, J., de Bergeyck, V., and Boone, T. (1990). Structure of the gene of turn- transplantation antigen P198: A point mutation generates a new antigenic peptide. J. Exp. Med. 172, 35-45.
128. Siliciano, R., Hemesath, T., Pratt, J., Dintzis, R., Dintzis, H., Acuto, O., Shin, H., and Reinherz, E. (1986). Direct evidence for the existence of nominal antigen binding sites of T cell surface Ti α-β heterodimers of MHC-restricted T cell clones. Cell 47, 161-171.
129. Sirokine, I., Ben-Mahrez, K., Bracone, A., Thierry, D., Ishii, S., Imamoto, F., and Kohiyama, M. (1991). Presence of circulating anti c-myb oncogene product antibodies in human sera. Int. J. Cancer 47, 665-669.
130. Spiropoulou, C. F., and Nichol, S. T. (1993). A small highly basic protein is encoded in overlapping frame within the P gene of vesicular stomatatis virus. J. Virol. 67,3103-3110.
131. Springer, G. F. (1984). T and Tn, general carcinoma autoantigens. Science 224,1198-1206.
132. Springer, G. F., Desai, P. R., Spencer, B. D., Tegtmeyer, H., Carlstedt, S. C., and Scanlon, E. F. (1995). T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced breast carcinoma. Cancer Det. Prev. 19, 374-380.
133. Srivastava, P. K., Udono, H., Blachere, N. E., and Li, Z. H. (1994). Heat-shock proteins transfer peptides during antigen processing and CTL priming. Immune-genetics 39,93-98.
134. Stancovasld, I., Hurwitz, E., Leitner, O., Ullrich, A., Yarden, Y., and Sela, M. (1991). Mechanistic aspects of the opposing effects of monoclonal antibodies to the erbB-2 receptor on tumor growth. Proc. Natl. Acad. Sci. USA 88, 8691-8695.
135. Steven, C. W., and Lane, D. P. (1992). Mutant confirmation of p53-precise epitope mapping using a filamentous phage epitope library. J. Mol. Biol. 225, 577-583.
136. Stevenson, F. K., Zhu, D., King, C. A., Ashworth, L. J., Kumar S., and Hawkins, R. E. (1995). Idiotypic DNA vaccines against B-cell lymphoma. Immunol. Rev. 145, 211-228.
137. ; Cahan, L. D., Tsuchida, T., Saxton, R. E., Irie, R. F., and Morton, D.L (1985). Immunogenicity of melanoma-associated gangliosides in cancer patients. Int. J. Cancer 35, 607-612.
138. Takahashi, T., Makiguchi, Y., Hinoda, Y, Kakiuchi, H., Nakagawa, N., Imai, K., and Yachi, A. (1994). Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC-1 from multiple myeloma p a t i e n t. J. Immunol 153, 2102-2109.
139. Tan, E. M. (1989). Antinuclear antibodies: Diagnostic markers for autoimmune disease. Adv. Immunol. 44, 93-151.
140. Taylor-Papadimitriou, J. (1991). Report on the First International Workshop on Carcinoma-Associated Mucins. Int. J. Cancer 49, 1-11.
141. Thomson, J., Grunert, F., and Ziemerman, W. (1991). CEA gene family: Molecular biology and clinical perspective, J. Clin. Lab. Anal. 5, 344-366.
142. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA 91, 9461-9465.
143. Traversari, C., van der Bruggen, P., Luescher, I. F., Lurquin, C., Chomez, P., Van Pel, A., De Plaen, E., Amar-Costesec, A., and Boone, T. (1992). A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen M Z 2 - E. J. Exp. Med. 176, 1453-1457.
144. Udono, H., and Srivastava, P. K. (1994). Comparison of tumor-specific immunogenicities of stress-induced proteins Gp96, Hsp90 and H s p 7 0. J. Immunol. 152, 5398-5403.
145. Urban, J. L., and Schreiber, H. (1992). Tumor antigens. Annu. Rev. Immunol. 10,617-644.
146. Van den Eynde, B., Peeters, O., De Backer, O., Gaugler, B., Lucas, S., and Boone, T. (1995). A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182, 689-698.
147. van der Bruggen, P., Szikora, J-P., Boel, P., Wildmann, C., Somville, M., Sensi, M., and Boon, T. (1994). Autologous cytolytic lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cwl601. Eur. J. Immunol. 24, 2134-2140.
148. van der Bruggen, P., Traversari, C., Chomez, P., Durquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647.
149. Van Elsas, A., Nijman, H. W., Van Der Minne, C. E., Mourer, J. S., Kast, W. M., Melief, C. J. M., and Schrier, P. I. (1995). Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21RAS peptide presented by HLA-A0201. Int. J. Cancer 61, 389-396.
150. Vanky F., and Klein, E. (1982). Specificity of auto-tumor cytotoxicity exerted by fresh, activated and propagated human T lymphocytes. Int. J. Cancer 29, 547-558.
151. Van Pel, A., van der Bruggen, P., Coulie, P. C, Brichard, V. G., Lethe, B., van den Eynde, B., Uyttenhove, C., Renauld, J.-C, and Boone, T. (1995). Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 145, 229-250.
152. Vijayasyradhi, S., Bouchard, B. B., & Houghton, A. N. (1990). The melanoma antigen gp75 is the human homologue to mouse b (BROWN) locus gene. J. Exp. Med. 171,1375-1380.
153. Vitetta, E., and Uhr, J. (1994). Monoclonal antibodies as agonists: An expanded role for their use in cancer therapy. Cancer Res. 54, 5301-5309.
154. Vogelstein, B., and Kinzler, K. W. (1992). p53 function and dysfunction. Cell 70, 523-526.
155. Von Knebel Doeberitz, M., Baukneckt, T., Bartsch, D., and Zur Hausen, H. (1991). Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. Proc. Natl. Acad. Sci. USA 88, 1411-1415.
156. Vuist, M. J., Levy, R., and Maloney, D. G. (1994). Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of Bcl-2 protein. Blood 83, 899-906.
157. Waldman, T. (1991). Monoclonal antibodies in diagnosis and therapy. Science (Washington DC) 252, 1657-1662.
158. Wang, M. C., Papsider, L. D., Kuriyama, M., Valenzuela, L. A., Murphy, G. P., and Chu, T. M. (1981). Prostate antigen: a new potential marker for prostatic cancer. Prostate 2, 89-96.
159. Wang, R.-F., Robbins, P. F., Kawakami, Y., Kang, X.-Q., and Rosenberg, S. A. (1995a). Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181, 799-804.
160. Wang, R. F., Parlehurst, M. R., Kawakami, Y., Robins, P. F., and Rosenberg, S. A. (1996). Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med., in press.
161. Wat, W. W. K., Lee, P.-J., MTimkulu, T., Chan, W.-P., and Loor, R. (1986). Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc. Natl. Acad. Sci. USA 83, 3166-3170.
162. Winter, S. F., Minna, J. D., Johnson, B. E., Takahashi, T., Gazdar, A., and Carbome, D. (1992). Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 52, 4168-4174.
163. Wolfel, T., Van pel, A., Brichard, V., Schneider, J., Seliger, B., Meyer zum Buschenfelde, and Boon, T. (1994). Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24, 759-764.
164. Yoshino, I., Peoples, G. E., Goedegebuure, P. S., Maziarz, R., and Eberlein, T. J. (1994a). Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian c a n c e r. J. Immunol. 152, 2393-2400.
165. Yoshino, I., Goedegebuure, P. S., Peoples, G. E., Parikh, A. S., DiMaio, M. J., Lyerly, H. K., Gazdar, A. F., and Eberlein, T. J. (1994b). HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res. 54, 3387-3390.
166. Yu, H., and Diamandis, E. P. (1995a). Prostate specific antigen in milk of lactating women. Clin. Chem. 41, 54-58.
167. Yu, H., and Diamandis, E. P. (1995b), Prostate specific antigen immunoreactivity in amniotic fluid. Clin. Chem. 41, 54-58.
168. Yu, H., Diamandis, E. P., Zarghami, N., and Grass, L. (1994). Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res. Treat. 32, 291-300.
169. Yu, H., Diamandis, E. P., Monne, M., and Croce, C. M. (1995a). Oral contraceptive-induced expression of prostate specific antigen in the female breast. J. Biol. Chem. 270, 6615-6618.
170. Yu, H., Giai, M., Diamandis, E. P., Katsaros, D., Sutherland, D. J. A., Levesque, M. A., Roagna, R., Ponzone, R., and Sismondi, P. (1995b). Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. 55,2104-2110.
171. Zhang, S., Walberg, L. A., Ogata, S., Itzkowitz, S. H., Rao Koganty, R., Reddish, M., Gandhi, S. S., Longenecker, S. H., Lloyd, K., and Livingston, P. O. (1995). Immune sera and monoclonal antibodies define two configurations for the sialyl Tn antigen. Cancer Res. 55, 3364-3368.
172. Zhao, X.-J., and Cheung, N.-K. (1995). GD2 oligosaccharide: Target for cytotoxic T lymphocytes. J. Exp. Med. 182, 67-74.
173. Zotter, S., Hageman, P. C., Lossnitzer, A., Mooi, W. J., and Hilgers, J. (1988). Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev. 11, 55-101.
174. Zur Hausen, H. (1994). Molecular pathogenesis of the cervix and its causation by specific human papillomavirus types. Curr. Top. Microbiol. Immunol. 186, 131-156.